DBV Technologies (DBVT) said Monday the US Food and Drug Administration has agreed with the company's proposal that the safety exposure data from the its phase 3 study for Viaskin peanut patch in four- to seven-year-olds will be enough to support a biologics license application filing in this age group.
The company plans to submit the application for the food allergies patch in H1 2026, potentially accelerating the product launch by about one year.
DBV said it had cash and cash equivalents of $32.5 million as of the end of 2024, likely not enough to support its operating plan for the next 12 months. As such, it said there's "substantial doubt" about its ability to continue as a going concern.
The company said it is actively reviewing potential financing and strategic options with its financial advisers.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。